posted
SREA(.32) to Partner with Major Developer in Shenyang with on Hand Projects Worth Over $175 Million Friday, June 29 2007 4:00 PM, EST HONG KONG , June 29 /Xinhua-PRNewswire-FirstCall/ -- Score One Inc. (OTC Bulletin Board: SREA) announced today that it is in negotiation with a major developer in China , Shenyang Paliburg Plaza Limited (''SPPL''), for the development of Dalian Fengming International Recreation Town Phase II (''Recreation Town''). The negotiation includes the acquisition of a majority stack in SPPL with the issuance of a convertible note and the co-development of Recreation Town. ''The potential co-operation with SPPL is a major break-through of Score One.,'' said Ms. Hoi-ho Kiu, Chairman and CEO of Score One, Inc. ''SPPL is a major real estate developer in Northern China who owns Paliburg Plaza, a real estate complex with assets value of over US$175 million in Shenyang , major city at Northern China PRC. With its local experience and market knowledge of SPPL of Northern China , we are confident that this cooperation will benefit both the Company and SPPL and lead to a lucrative and fruitful future for our Recreation Town development of bungalows in Dalian, Northern China .'' About Shenyang Paliburg Plaza Limited SPPL owns Shenyang Paliburg Plaza and Shenyang Grant Century Hotel located in Shenyang , one of the capital cities at Northern China , PRC. Shenyang Paliburg Plaza comprises of a 20-storey service apartment tower and a 20-storey 4-star hotel. Together with the 8-storey retail podium and 2-storey basement, the Shenyang Paliburg Plaza has a total gross floor area of approximately 96,000 square meters with a current valuation of over US$175 million . About Score One Inc. Score One Inc. is a comprehensive investment service group and the parent company of RC Capital Limited , a Hong Kong based corporation which business includes financial consultation, investment and financial planning, enterprise re-organization, public offering consultation, and direct investment. Recreation Town is a piece of undeveloped land located in the peninsula in Dalian, the PRC with a current market value exceeding $75 million . Safe Harbor Information in this news release or on this website may contain statements about future expectations, plans, prospects or performance of Score One Inc. that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be,'' "expects,'' "may affect,'' "believed,'' "estimate,'' "project,'' and similar words and phrases are intended to identify such forward-looking statements. Score One Inc. cautions you that any forward-looking information provided by or on behalf of Score One Inc. is not a guarantee of future performance. None of the information on this website constitutes an offer to sell securities or investment advice of any kind, and visitors should not base their investment decisions on information contained in this website. Score One Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Score One Inc.'s control. In addition to those discussed in Score One Inc.'s press releases, public filings, and statements by Score One Inc.'s management, including, but not limited to, Score One Inc.'s estimate of the sufficiency of its existing capital resources, Score One Inc.'s ability to raise additional capital to fund future operations, Score One Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Score One Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Score One Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. For more information, please contact:
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
MNCL(.019) Retail Division Receives Second Purchase Order from Canada's Largest Book Retailer Friday, June 29 2007 4:04 PM, EST RENO, Nev .--(BUSINESS WIRE)-- Martin Nutraceuticals, Inc. (PINKSHEETS: MNCL) is pleased to announce that it has received a second purchase order from Chapters Book Stores for their breakthrough book: Medical Crisis: Secrets Your Doctor Won't Share With You. Chapters Book Stores, whose parent company Indigo Books and Music (TSX: IDG) represents over half of all book sales in Canada with revenues exceeding $300 million annually, is Canada's largest big box retailer with over 77 branded super stores and 280 mall-based stores across Canada . Chapter/Indigo not only was the first to feature an elegant interior to enhance the book reading experience, but has now added the mega-coffee provider Starbucks (NASDAQ: SBUX) to increase the comfort of all visitors. "We are very pleased that we are beginning to receive re-orders from highly respected book stores like Chapters. We are also confident that our new book Medical Crisis: Secrets Your Doctor Won't Share With You will be a success, and are very pleased that our book is now sharing shelf space with best selling health and wellness books such as Natural Cures," commented Harvey Panesar, President of Martin Nutraceuticals. "As an organization, our focus remains with the DRTV (infomercial) in the United States ; however, we recognize the great opportunity afforded us through our retail division to have product in recognizable book retailers such as Chapters in Canada . We now intend to continue to enter the U.S. market targeting retail placement in such well-known book stores as Borders and Barnes and Noble," Panesar continued. For more information, please contact Investor Relations at (973) 351-3868 or http://www.martinnutra.com/ About Indigo Books & Music Inc. Indigo is a Canadian company and the largest book retailer in Canada , operating bookstores in all provinces under the names Indigo Books Music & More, Chapters, The World's Biggest Bookstore and Coles. Indigo operates chapters.indigo.ca, an online retailer of books, music, videos, and DVDs. It is a publicly traded company listed on the Toronto Stock Exchange under the stock symbol IDG. About Martin Nutraceuticals Inc. Martin Nutraceuticals Inc. is a company focused on providing improved health and lifestyle through natural products. Martin Nutraceuticals flagship products include Arthrizyme(TM) for general joint pain and Oxygenol(TM) for anti-oxidation and Maximum Slim(TM) for weight control. The company has recently produced an Infomercial featuring best-selling author Dr. Anthony Martin's new book "Medical Crisis: Secrets Your Doctor Won't Share With You". This amazing new book provides Dr. Martin's insights into the many things that an individual can eat and do in order to improve their health and wellness. The book focuses on providing information that medical doctor do not have the time or the resources to provide to their patients. The book has been described as life-altering and in some instances life-saving. Safe Harbor Statement This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The risks and uncertainties that may affect the operations, performance development and results of the Companies business include but are not limited to fluctuations in the financial results, availability and customer acceptance of our products and services, the impact of competitive products, services and pricing, general market trends and conditions. Source: Martin Nutraceuticals, Inc.
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
VGNI(.03) Announces Plan to Optimize Capital Structure June 29, 2007 - 4:15 PM PLANTATION, Fla., June 29 /PRNewswire-FirstCall/ -- Viragen International, Inc. (OTC Bulletin Board: VGNI), a majority-owned subsidiary of Viragen, Inc. (Amex: 'VRA'; 'VRA.U'; 'VRA.WS'), today announced that its Board of Directors and the holder of a majority of its outstanding common stock have approved and authorized a 1-for-40 reverse stock split, as part of a plan to optimize the Company's capital structure and enter into new strategic initiatives and financing agreements.
The reverse split was approved and authorized by VRA, under Delaware law, without a stockholders' meeting, as it owns approximately 77% of VGNI. A preliminary information statement related to this transaction has been filed with the SEC, and a definitive information statement will be filed and mailed to stockholders soon after completion of regulatory review. The reverse stock split is expected to take place approximately 20 days following mailing of the definitive information statement to stockholders.
The reverse stock split will affect all shares of Viragen International's common stock, including those shares underlying stock options outstanding immediately prior to the effective date of the reverse stock split.
In the reverse stock split, each 40 shares of Viragen International's issued and outstanding common stock will be automatically converted into one share of common stock, reducing the number of Viragen International's outstanding shares from approximately 77.7 million shares to approximately 1.94 million shares. No fractional shares will be issued in connection with the reverse stock split. Instead, the Company will round up any fraction to the nearest whole share. As a result, each stockholder whose shares of common stock are not evenly divisible by forty will receive one additional share of common stock for the fractional shares of common stock that such stockholder would otherwise be entitled to receive as a result of the reverse stock split.
Stockholders whose shares are held in brokerage accounts need take no action for their brokers to receive post-split stock certificates. Stockholders of record should not tender pre-split stock certificates in exchange for post-split certificates at this time. Following the reverse stock split, stockholders of record will receive instructions on how they can exchange their pre-split certificates for post-split certificates.
Shortly before the effective date of the reverse stock split, the Company's common stock will be assigned a new CUSIP identification number and trading symbol. The Company will issue a press release disclosing the new CUSIP number and symbol once they have been assigned.
About Viragen International, Inc.:
With international operations in the U.S., Scotland and Sweden, we are a bio-pharmaceutical company engaged in the research, development, manufacture, and commercialization of Multiferon(R) (multi-subtype, human alpha interferon), which is uniquely positioned in valuable niche indications, such as high-risk malignant melanoma, other niche cancer indications and selected infectious diseases.
We are a majority-owned subsidiary of Viragen, Inc. and operate through our foreign wholly-owned subsidiaries: ViraNative AB, a company located in Umea, Sweden; and Viragen (Scotland) Limited, a company located near Edinburgh, Scotland.
Viragen, Inc. Corporate Contact: Douglas Calder, Director of Communications Phone: (954) 233-8746; Fax: (954) 233-1414 E-mail: dcalder*viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as 'believes,' 'expects,' 'potential,' 'plans,' 'suggests,' 'may,' 'should,' 'could,' 'intends,' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the success of third- party marketing efforts; our ability to retain third-party distributors; our ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Viragen International, Inc.
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
